Tony Zook serves as Director and Chief Executive Officer of NeoGenomics, Inc., a leading provider of cancer genetics diagnostic testing and global contract research services. With over two decades of experience in finance and operations within the healthcare and diagnostics sectors, Zook joined NeoGenomics in 2011 as Vice President of Finance. Prior to that, he spent eight years at PricewaterhouseCoopers (PwC), where he advanced to manager in the assurance and business advisory services practice, honing his expertise in financial reporting, audits, and strategic advisory for life sciences companies. Zook holds a Bachelor of Science in Accounting from Florida State University. Rising through the ranks at NeoGenomics, Zook was promoted to Chief Financial Officer in 2015 and later to Executive Vice President and CFO, overseeing significant growth initiatives. Under his financial leadership, the company executed key acquisitions such as the 2021 purchase of Inivata, a leader in liquid biopsy technology, and navigated complex financial restructurings, including a comprehensive debt refinancing in 2023 that strengthened the balance sheet and positioned NeoGenomics for accelerated expansion. His strategic oversight contributed to revenue growth exceeding $500 million annually and expanded the company's global footprint in precision oncology. Appointed CEO and elected to the Board of Directors in June 2024, Zook now leads NeoGenomics' mission to advance cancer care through innovative genomic testing and research services. His vision emphasizes operational excellence, innovation in companion diagnostics, and partnerships to deliver personalized medicine solutions, building on the company's legacy as a trusted partner to oncologists worldwide.